You are here

  • Home
  • Archive
  • Volume 9, Issue 4
  • Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial

Article info

Article menu
Oncolytic and local immunotherapy
Original research
Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial

Authors

  • Bo Zhang Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Jing Huang Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China PubMed articlesGoogle scholar articles
  • Jialin Tang Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Sheng Hu Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China PubMed articlesGoogle scholar articles
  • Suxia Luo Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China PubMed articlesGoogle scholar articles
  • Zhiguo Luo Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, China PubMed articlesGoogle scholar articles
  • Fuxiang Zhou Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China PubMed articlesGoogle scholar articles
  • Shiyun Tan Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China PubMed articlesGoogle scholar articles
  • Jieer Ying Department of Abdominal Oncology, Institute of Cancer Research & Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China PubMed articlesGoogle scholar articles
  • Qing Chang Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Rui Zhang Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Chengyun Geng Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Dawei Wu Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Xiangyong Gu Binhui Biopharmaceutical Co., Ltd, Wuhan, China PubMed articlesGoogle scholar articles
  • Binlei Liu Binhui Biopharmaceutical Co., Ltd, Wuhan, ChinaNational “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Hubei University of Technology, Wuhan, China PubMed articlesGoogle scholar articles

Citation

Zhang B, Huang J, Tang J, et al
Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial
Journal for ImmunoTherapy of Cancer 2021;9:e002224. doi: 10.1136/jitc-2020-002224
Online issue publication 
May 06, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.